{"entity":{"id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of F182112, Pomalidomide in multiple myeloma, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.","summary":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07312188 by Shandong New Time Pharmaceutical Co., LTD, with 90 participants planned, started 2025-07-02 and due to reach its primary completion in 2028-05-20. Interventions recorded: F182112+P, F182112+CD38. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07312188","url":"https://clinicaltrials.gov/study/NCT07312188"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["f182112","pomalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07312188","phase":"2","setting":"A Phase II Study of F182112 Combined With Different Administration Regimens in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Shandong New Time Pharmaceutical Co., LTD","enrolled":90,"outcomes":[]},"route":"/trials/nct07312188/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/"}]}}